Integra Lifesciences IART
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$2.56M (7 inflow days, 13 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 44.8% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 8.67% to 10.15% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Dimensional Fund Advisors | Mutual Fund | 2026/Q3 | +548,778 | 3.6% |
| LSV Asset Management | Mutual Fund | 2026/Q3 | +500,349 | 0.9% |
| Invesco Ltd. | Mutual Fund | 2026/Q3 | +391,757 | 4.9% |
| JPMorgan Chase & Co. | Public Company | 2026/Q3 | +391,117 | 0.6% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +196,675 | 5.1% |
| Access Investment Management, LLC | Mutual Fund | 2026/Q3 | +159,980 | 0.7% |
| Morgan Stanley | Public Company | 2026/Q3 | +147,655 | 4.8% |
| BlackRock | Mutual Fund | 2026/Q3 | +141,825 | 13.9% |
| Russell Investment Management, LLC | Mutual Fund | 2026/Q3 | +134,320 | 0.2% |
| PanAgora Asset Management, Inc. | Mutual Fund | 2026/Q3 | +120,349 | 0.2% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +160,130 | 0.2% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +816,894 | 1.9% |
| Integral Health Asset Management, LLC | Hedge Fund | 2026/Q3 | +550,000 | 0.7% |
| BlackRock | Mutual Fund | 2026/Q3 | +364,934 | 13.7% |
| Invesco Ltd. | Mutual Fund | 2026/Q3 | +354,779 | 4.4% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 30 Sep 2026 | Andrea Caruso | CVP & CHRO | Initial Statement of Beneficial | +0 | – | 24,211 |
| 16 Sep 2026 | Lesha Shinn | Initial Statement of Beneficial | +0 | – | 26,838 | |
| 31 Aug 2026 | Chantal Veillon-Berteloot | Former Chief Human Resources Officer | Sale to Issuer | -1,455 | $16.62 | 20,772 |
| 2 Jul 2026 | Lea Knight | Chief Financial Officer | Sale to Issuer | -5,226 | $18.05 | 45,263 |
| 30 Jun 2026 | Robert Davis | Executive Vice President of Tissue Reconstruction and Distributed Technologies | Other Derivative Acquisition | +11,180 | – | 54,530 |
| 30 Jun 2026 | Jeffrey Mosebrook | Senior VP of Finance & Principal Accounting Officer | Sale to Issuer | -937 | $17.89 | 34,516 |
| 30 Jun 2026 | Harvinder Singh | Executive VP & President of International Business | Other Derivative Acquisition | +5,590 | – | 68,883 |
| 31 May 2026 | Stuart Essig | Chief Executive Officer | Other Derivative Acquisition | +365,297 | – | 365,297 |
| 31 May 2026 | Stuart Essig | Chief Executive Officer | Other Derivative Acquisition | +705,468 | $15.67 | 705,468 |
| 31 May 2026 | Michael McBreen | Executive Vice President | Other Derivative Acquisition | +31,909 | – | 124,017 |
| 31 May 2026 | Michael McBreen | Executive Vice President | Other Derivative Acquisition | +60,372 | $15.67 | 60,372 |
| 8 May 2026 | Keith N. Bradley | Independent Director | Sale to Issuer | -882 | $13.92 | 88,254 |
| 6 May 2026 | Christian Schade | Independent Director | Other Derivative Acquisition | +17,700 | – | 17,700 |
| 6 May 2026 | Barbara Hill | Independent Director | Other Acquisition | +24,338 | – | 187,541 |
| 6 May 2026 | Keith N. Bradley | Independent Director | Other Derivative Acquisition | +17,700 | – | 17,700 |
| 6 May 2026 | Jeffrey Graves | Independent Director | Other Derivative Acquisition | +17,700 | – | 17,700 |
| 6 May 2026 | Shaundra Clay | Independent Director | Other Derivative Acquisition | +17,700 | – | 17,700 |
| 6 May 2026 | Renee Lo | Independent Director | Other Derivative Acquisition | +17,700 | – | 17,700 |
| 10 Mar 2026 | Robert Davis | Executive Vice President of Tissue Reconstruction and Distributed Technologies | Other Derivative Acquisition | +43,350 | – | 43,350 |
| 10 Mar 2026 | Mojdeh Poul | Former Chief Executive Officer | Other Derivative Acquisition | +343,393 | – | 445,691 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 7,895,702 | 10.1% | 6.4 |
| 15 Oct 2026 | 7,316,999 | 9.4% | 5.5 |
| 30 Sep 2026 | 7,266,960 | 9.3% | 7.5 |
| 15 Sep 2026 | 6,806,086 | 8.8% | 8.3 |
| 31 Aug 2026 | 6,858,036 | 8.8% | 12.3 |
| 14 Aug 2026 | 6,742,359 | 8.7% | 10.0 |
No comments yet — be the first to weigh in on IART.
Sign in to join the discussion.